Prostate Cancer
Prostate Cancer
Katy MarshallCRPC | April 10, 2024
The data were sourced from a deidentified US-based metastatic prostate cancer clinicogenomic database.
Read More
Leonard Gomella, MD, FACSProstate Cancer Diagnostics | April 10, 2024
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Marco Finati, MDProstate Cancer | April 9, 2024
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Emily MenendezProstate Cancer Diagnostics | April 10, 2024
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
Steven Canfield, MDLocalized | April 9, 2024
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
Zachary BessetteLocalized | April 9, 2024
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
Emily MenendezLocalized | April 8, 2024
cN1 patients with PCa who undergo initial treatment with RT have worse PCSM outcomes than those treated with RP.
Daniel Spratt, MDLocalized | April 5, 2024
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
Shilpa Gupta, MDProstate Cancer | April 5, 2024
Dr. Gupta traces the trajectory of her career and describes her commitment to advancing the field through innovative trials.
James Sylora, MDLocalized | April 3, 2024
Dr. James Sylora shares his career, patient care, and vision for surgical and therapy advancements in community urology.
Leah LawrenceProstate Cancer Diagnostics | April 8, 2024
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Katy MarshallCRPC | April 1, 2024
OS was compared using Cox proportional hazards models with IPTW adjusted for baseline characteristics.
David Ambinder, MDProstate Cancer | March 29, 2024
Drs. Ambinder and Elsamra explore robotic surgery, including its applicability, patient benefits, and evolving role.
Emily MenendezmCSPC | March 26, 2024
A combination of androgen annihilation therapy with radiotherapy was tested for recurrent metastatic prostate cancer.
Katy MarshallProstate Cancer Diagnostics | March 25, 2024
Cohort 4 of the trial is the final dose-escalation phase and will be followed by a dose-expansion phase.
Gary Kirsh, MDProstate Cancer | March 22, 2024
Dr. Kirsh discusses his distinguished career and the evolution of urology practice in the United States.
Jérémie Calais, MD, PhDProstate Cancer Diagnostics | March 21, 2024
The panel continues discussing their phase 3 PSMA PET/CT trial expectations for the final data readout in 2025.
Jérémie Calais, MD, PhDProstate Cancer Diagnostics | March 21, 2024
The panel from UCLA highlights their study on the impact of PSMA PET/CT on prostate cancer salvage radiotherapy management.
Emily MenendezLocalized | March 21, 2024
Relugolix was approved in 2020 for the treatment of localized prostate cancer based on the efficacy seen in the HERO trial.
Emily MenendezProstate Cancer | March 19, 2024
The NRG-GU003 trial examined patients with prostate cancer who underwent hypofractionated and conventional radiotherapy.